Helicobacter pylori infection
Conditions
Interventions
V1 group:Vonoprazan 20mg bid, amoxicillin 1.0g tid, for two weeks, group
V2 group:Vonoprazan 20mg, amoxicillin 1.0g, furazolidone 100mg, bismuth citrate potassium 240mg, all twice daily for two weeks
V3 group:Ilaprazole 5mg, amoxicillin 1.0g, furazolidone 100mg, bismuth potassium citrate 240mg, all twice daily for two weeks
Sponsors
Department of Gastroenterology, Second Affiliated Hospital of Hainan Medical College
Eligibility
Sex/Gender
All
Age
20 Years to 68 Years
Inclusion criteria
Inclusion criteria: (1) HP-infected patients aged 18-75 years with positive 13C-urea breath test, symptomatic or asymptomatic; (2) these infected patients had no previous serious liver insufficiency, renal insufficiency, or gastrointestinal tumors, and no history of PPIs, antibiotic, or other drug use within the past four weeks, as these factors were considered to affect eradication; (3) the patients agreed to participate in the study and signed an informed consent form
Exclusion criteria
Exclusion criteria: (1) history of gastrointestinal tumors or surgery; (2) allergy to any of the drugs in the study; (3) patients with severe psychiatric disorders that prevent communication; (4) refusal to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Carbon 13 breath test or carbon 14 breath test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactFeihu Bai
Department of Gastroenterology, Second Affiliated Hospital of Hainan Medical College
Outcome results
None listed